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Abstract
Detrimental inflammation of the lungs is a hallmark of severe influenza virus infections. Endothelial cells are the source of
cytokine amplification, although mechanisms underlying this process are unknown. Here, using combined pharmacological
and gene-deletion approaches, we show that plasminogen controls lung inflammation and pathogenesis of infections with
influenza A/PR/8/34, highly pathogenic H5N1 and 2009 pandemic H1N1 viruses. Reduction of virus replication was not
responsible for the observed effect. However, pharmacological depletion of fibrinogen, the main target of plasminogen
reversed disease resistance of plasminogen-deficient mice or mice treated with an inhibitor of plasminogen-mediated
fibrinolysis. Therefore, plasminogen contributes to the deleterious inflammation of the lungs and local fibrin clot formation
may be implicated in host defense against influenza virus infections. Our studies suggest that the hemostatic system might
be explored for novel treatments against influenza.
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Introduction
Influenza A viruses (IAV) are an important cause of outbreaks of
respiratory tract infections and are responsible for significant
morbidity and mortality in the human population [1]. Upon
infection with IAV, innate and adaptive immune responses are
induced that restrict viral replication and that afford protection
against infection with these viruses. However, excessive inflam-
mation, particularly in the lower respiratory tract, may result in
alveolar damage limiting respiratory capacity and deteriorate the
clinical outcome of IAV infections [2,3]. Dys-regulation of
cytokine production in the lungs is thus often associated with a
fatal outcome of IAV [4]. The sites of virus replication in the
respiratory tract represent complex microenvironments, in which
extracellular proteases are present abundantly [5,6]. Some of these
proteases can play a role in innate immune responses since they
are important mediators of inflammatory processes [7] and
influence virus replication [8,9]. To date, however, the elucidation
of host proteases contributing to pathogenesis of IAV infections in
vivo has been hampered by the lack of experimental models.
One of the proteases of interest is plasmin, which is a serine
protease involved in fibrinolysis, the biological process of dissolving
fibrin polymers into soluble fragments. Plasmin is generated
through cleavage of the proenzyme plasminogen, produced in the
liver and present in the blood. Specific binding and conversion of
plasminogen into plasmin by IAV may afford the virus an
alternative protease for cleavage of its hemagglutinin molecule
[10,11]. This is an essential step in the virus replication cycle and
this may contribute to the pathogenesis of IAV infection [12,13].
In addition, plasminogen/plasmin plays a central role in
fibrinolysis-mediated inflammation [14] and there is evidence of
fibrinolysis activation during IAV infections [15]. Thus, plasmin-
ogen could contribute to the pathogenesis of IAV infections by
promoting virus replication or by inducing a fibrinolysis-depen-
dent harmful inflammatory response in the respiratory tract. At
present it is unknown whether one or both of these two
mechanisms of plasminogen activity contribute to pathogenesis
of IAV infections in vivo. In the present study we address this
research question and using plasminogen-deficient mice (PLG-
KO) and pharmacological approaches the role of plasminogen
during IAV infections was investigated.
Our findings show that plasminogen plays an important role in
lung inflammation upon IAV infections, mainly through fibrino-
lysis. Therefore, targeting host factors, such as the fibrinolytic
molecule plasminogen may be of interest for the development of
new therapeutics against IAV infections.
PLOS Pathogens | www.plospathogens.org 1 March 2013 | Volume 9 | Issue 3 | e1003229
Results
Plasminogen promotes IAV pathogenesis
To explore the role of plasminogen in IAV pathogenesis, we
investigated the consequence of plasminogen-deficiency. Plasmin-
ogen +/2 mice were intercrossed to generate wild-type (WT) and
plasminogen2/2 (PLG-KO) mice, which were infected with IAV
A/PR/8/34 (H1N1; 50,000 or 500 PFU) and weight loss and
survival rates were monitored. As shown in Figure 1A, compared
to WT mice, PLG-KO mice were significantly more resistant to
IAV-induced weight loss and death. In PLG-KO mice substantial
protection was also observed against infection with 2009 pandemic
virus A/Netherlands/602/09 (30,000 PFU, Figure 1B) and highly
pathogenic H5N1 virus A/chicken/Ivory-Coast/1787/2006 (10
EID50 H5N1, Figure 1C). Of note, the latter was not adapted to
replicate in mammals, which could explain the delay in weight loss
observed upon infection, as also observed by others [16]. Thus, we
concluded that without plasminogen, pathogenesis of IAV
infections was dampened and mortality reduced in a subtype-
independent manner.
Protection conferred by PLG-deficiency is independent
on virus replication
To gain further insight into the role of plasminogen in virus
replication, A549 cells were infected with IAV in the absence or
presence of plasminogen. Interestingly, plasminogen supported the
replication of IAV A/PR/8/34 but not that of A/Netherlands/
602/09 (Figure 2A). In contrast, trypsin supported replication of
both viruses while no replication was observed in absence of
proteases. Since plasminogen promotes IAV replication through
HA cleavage [11], plasminogen-mediated HA cleavage of both
viruses was compared (Figure 2B). In absence of proteases (2),
HA0 precursor protein was detected in A549 cells infected with
either virus. In presence of plasminogen (PLG), an additional
band, corresponding to HA2 [11] was detected at 25 kDa in A/
PR/8/34, but not in A/Netherlands/602/09 infected cells. In
presence of trypsin (Try), HA2 was detected in cells infected with
either virus. Similar levels of tubulin were detected, which was
included as control cellular protein. Thus, plasminogen promotes
cleavage of HA of IAV A/PR/8/34 but not that of A/
Netherlands/602/09, which correlated with differences in repli-
cative capacity of these viruses in presence of plasminogen.
On day 2 post-inoculation with IAV A/PR/8/34, mean lung
virus titer of PLG-KO mice was significantly lower than that of
WT mice (Figure 2C). This difference was not observed for IAV
A/Netherlands/602/09. For both viruses, and at the other days
post-infection, no significant differences in lung virus titers were
observed between PLG-KO and WT mice. Thus, in vivo,
plasminogen promoted early virus replication of IAV A/PR/8/
34 but not of A/Netherlands/602/09. Since the absence of
plasminogen protected mice against both viruses, the deleterious
effect of plasminogen was most likely independent of virus
replication in the lungs.
Pulmonary injury and virus dissemination
To assess possible other contributions of plasminogen to the
pathogenesis of IAV infections, inflammation of the lungs and viral
dissemination were examined after infection of mice with IAV A/
PR/8/34 or A/Netherlands/602/09. At day 3 post-infection,
extensive alveolar damage and marked cellular infiltrates were
observed in lungs of WT mice in contrast to those of PLG-KO
mice (HE) after A/PR/8/34 virus infection (Figure 3A, left panel).
This difference was also observed upon infection with A/
Netherlands/602/09 virus, at day 5 (Figure 3A, right panel) but
not at day 3 post-inoculation (data not shown). For all conditions,
in WT and PLG-KO mice, similar numbers of IAV-infected cells
were detected by immunohistochemistry (IHC). Also, no lesions
were observed in Mock-infected mice (data not shown). Thus,
plasminogen-deficiency protected mice against inflammation
induced by A/PR/8/34 and A/Netherlands/602/09 viruses,
showing that plasminogen plays a deleterious role in lung
inflammation, independent of virus replication in the lungs.
To investigate the difference in pulmonary inflammation
between PLG-KO and WT mice, cytokine levels in the
bronchoalveolar lavages (BALs) were assessed by ELISA
(Figure 3B) or a luminex-based cytokine detection assays
(Figure 4A) at various time point post-infection. Upon inoculation
of A/PR/8/34 virus, both in PLG-KO and WT mice, BAL
cytokine levels increased 2 and 5 days post-inoculation. However,
in BAL of PLG-KO mice cytokine levels were considerably and
significantly lower than in those of WT littermates (see scale
differences for Figure 4A), which correlated with reduced IAV-
induced lung inflammation in absence of plasminogen. Upon A/
Netherlands/602/09 virus infection, release of cytokines in the
BAL was also significantly higher in WT mice compared to PLG-
KO mice at day 5 but not at day 2 post-inoculation (Figure 3B,
right panel). Thus in concordance with the histological analysis,
plasminogen promoted lung inflammation of IAV A/PR/8/34
and A/Netherlands/602/09 viruses, showing that the effect is
most likely independent of virus replication in the lungs.
Furthermore, in PLG-KO mice the virus failed to disseminate to
extra pulmonary organs unlike in WT mice, upon intranasal
infection with A/PR/8/34 virus (500 PFU) (Figure 4B). Especially
high virus titers were detected in the liver, the source of
plasminogen. Collectively, these results suggest that plasminogen
plays an important role in promoting the inflammatory response
and virus dissemination to extra-pulmonary organs during IAV-
infection.
Fibrinolysis and IAV pathogenesis
Since degradation of fibrin is one of the main functions of
plasminogen/plasmin, we hypothesized that the host fibrinolytic
system plays a role in the pathogenesis of IAV infection. First, we
investigated whether IAV infection induced fibrinolysis. To this
end, mice were inoculated with IAV A/PR/8/34 and at various
time points post-inoculation, the level of fibrinolysis markers in
BALs was assessed by ELISA (Figure 5A). Plasminogen and active
plasmin levels were barely detectable in the BAL of uninfected
mice but their levels significantly increased during the course of
infection. Levels of fibrinogen also significantly increased at day 4
post-infection and then dropped at days 5 and 6, suggesting a
recruitment of fibrinogen to the lungs and a rapid consumption of
Author Summary
Influenza viruses, including H5N1 bird influenza viruses
continue to form a major threat for public health. Available
antiviral drugs for the treatment of influenza are effective
to a limited extent and the emergence of resistant viruses
may further undermine their use. The symptoms associat-
ed with influenza are caused by replication of the virus in
the respiratory tract and the host immune response. Here,
we report that a molecule of the fibrinolytic system,
plasminogen, contributes to inflammation caused by
influenza. Inhibiting the action of plasminogen protected
mice from severe influenza infections, including those
caused by H5N1 and H1N1 pandemic 2009 viruses and
may be a promising novel strategy to treat influenza.
Plasminogen and Influenza A Virus Infections
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Figure 1. Plasminogen contributes to influenza pathogenesis. Survival and weight loss of PLG-KO (triangles) and WT (squares) mice infected
with (A) IAV A/PR/8/34 (50,000 PFU; n = 11–21 or 500 PFU; n = 23–24), (B) A/Netherlands/602/09 (30,000 PFU; n = 7) or (C) A/chicken/Ivory-Coast/
1787/2006 (10 EID50; n = 12). The proportion of survival was determined based on euthanasia criteria. Animals that lost 20% of their body weight
were considered to have reached humane endpoints and were sacrificed according to the study protocol. It is of note that upon WT mice infection
with A/chicken/Ivory-Coast/1787/2006, all infected mice lost weight but died before reaching220% of their body weight, in contrast to PLG-KO mice,
which explains the difference in mortality but not in weight loss. Weight loss data represent weight average 6 s.e.m of the above indicated number
of mice. n =mice per group.
doi:10.1371/journal.ppat.1003229.g001
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the molecule and fibrinolysis. Finally, levels of FDP and D-dimers,
degradation products of fibrinolysis, significantly increased upon
infection, reaching 45 and 13 ng/ml respectively on day 6 post-
inoculation. Similar results were also obtained upon infection with
influenza virus A/Netherlands/602/09 (Figure 5A). As expected,
in the BAL of infected PLG-KO mice, used as negative control,
Figure 2. The deleterious role of plasminogen is independent on virus replication. (A) Virus replication of IAV A/PR/8/34 and A/
Netherlands/602/09 after inoculation of A549 cells in presence or absence (triangle) of plasminogen (square) or trypsin (circle). Data represent mean
6 s.e.m of three independent experiments. (B) Western blot analysis of A/PR/8/34 and A/Netherlands/602/09 HA cleavage after infection of A549 cells
in presence or absence of plasminogen (PLG) or trypsin (Try). Membranes were probed with anti-HA and anti-tubulin antibodies. kDa (apparent
molecular weight). NI stands for uninfected. (C) Infectious A/PR/8/34 (n = 3–5) and A/Netherlands/602/09 (n = 3) lung virus titers at the indicated time
points post-inoculation of WT (black bars) or PLG-KO mice (white bars). Data represent mean 6 s.e.m of 3–5 individual mice per group. n =mice per
group and per time-point.
doi:10.1371/journal.ppat.1003229.g002
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fibrinolysis markers were barely detectable. Thus, IAV infection
induced fibrinolysis. These results were confirmed by Western blot
analysis using an antibody directed against the mouse Aa chain of
fibrinogen (Figure 5B), which recognizes purified mouse fibrinogen
at a molecular weight of 66 kDa (data not shown). Compared to
uninfected mice (2), fibrinogen was readily detectable 2–6 days
post-inoculation in the lungs of infected mice. In the tissues, no
marked fibrinogen consumption was detected but during the
course of IAV infection, additional smaller bands corresponding to
FDP were observed in mouse lungs. These findings confirmed that
fibrinolysis took place during IAV infections in vivo.
To simulate the depletion of fibrin (and therefore fibrinolysis),
mice were treated with the snake venom Ancrod, a thrombin-like
protease that cleaves the Aa chain of fibrinogen, enhancing its
degradation and severely reducing its plasma levels (Figure 5C).
Treatment with Ancrod significantly increased IAV-induced
weight loss and mortality compared to vehicle-treated mice, but
had no effect on uninfected control mice (Figure 6A). This
increased mortality was also associated with an increase in
inflammation of the lungs, as detected by elevated cytokine levels
in the BAL (Figure 6B, WT). Of particular interest, the level of
interferon-gamma was barely detectable in untreated mice but
severely increased upon ancrod treatment. Thus, degradation of
fibrin(ogen) contributed to inflammation and increased pathoge-
nicity of IAV infection.
Plasminogen promotes IAV pathogenesis through
fibrinolysis
Next, we investigated whether Ancrod treatment could reverse
the protective effect of plasminogen-deficiency in terms of
inflammation and mortality rate. Again, PLG-KO mice were
protected from lung inflammation (p,0,05, between WT versus
PLG-KO), as judged from cytokine responses (Figure 6B) and
from IAV-induced mortality (Figure 6C). Interestingly, Ancrod-
treatment reversed the protection observed in the absence of
plasminogen and cytokine responses and mortality rates were
similar to those of Ancrod treated WT mice (Figure 6B and C,
p.0.05, between WT-treated and PLG-KO-treated ancrod).
Ancrod had no effect in uninfected mice (Figure S1). Thus,
fibrinolysis contributes to inflammation and pathogenesis of IAV
infections, which is mediated by plasminogen.
To further confirm if the deleterious role of plasminogen is
caused by fibrinolysis, we tested the outcome of infection of mice
after treatment with Ancrod and/or 6-aminohexanoic acid (6-
AHA). Indeed, 6-AHA is a lysine analogue that binds to the lysine
binding sites of plasminogen, inhibiting plasminogen-binding to
fibrin(ogen) and plasmin-mediated fibrinolysis [17]. First, 6-AHA
treated mice inoculated with 5,000 or 500 PFU of A/PR/8/34
were significantly more resistant to infection than untreated mice
(Figure 7A) and this protection correlated with reduced inflam-
mation in 6-AHA treated animals (Figure S2). Also, lung virus
titers were significantly lower in 6-AHA-treated mice compared to
untreated mice, at day 2 but not at days 3 or 5 post-infection
(Figure 7B). Thus, inhibition of plasminogen fibrinolytic activity
protected mice from developing pneumonitis and severe disease.
Furthermore, Ancrod-treatment of 6-AHA treated mice over-rode
the protective effect of 6-AHA, again resulting in IAV-induced
mortality (Figure 7A, lower panel). Administration of Ancrod and/
or 6-AHA had no effect in uninfected mice (Figure S3). Thus, the
protective effect of 6-AHA was reversed by Ancrod-mediated
fibrinogen degradation, demonstrating that plasminogen contrib-
uted to pathogenesis of IAV infection through fibrinolysis
activation.
6-AHA protects against influenza
Preventing deleterious inflammation after IAV infection could
be a promising new strategy to treat IAV infections. Therefore, we
investigated whether blocking the fibrinbolytic activity of plasmin-
ogen by 6-AHA administration at a later time point post-
inoculation was still protective. WT mice were inoculated with
IAV A/PR/8/34 and treated or not with 6-AHA, two days later.
As shown in Figure 7C, treatment with 6-AHA improved the
outcome of infection and prevented mortality. 6-AHA treatment
also protected mice from infection with A/Netherlands/602/09
and highly pathogenic H5N1 viruses (Figure 7C, lower panels).
Thus, blocking plasminogen-mediated fibrinolysis protected mice
against infections with various and highly pathogenic IAVs.
Discussion
The present study showed for the first time that fibrinolysis plays
a central role in the inflammatory response and the pathogenesis
Figure 3. Plasminogen-deficiency prevents severe inflamma-
tion. (A) Histopathological analysis of lungs from infected WT and PLG-
KO mice inoculated with A/PR/8/34 virus (day 3 post-infection) or A/
Netherlands/602/09 virus (day 5 post-infection). Thin sections of lungs
obtained from infected and uninfected WT and PLG-KO mice (as
indicated) were stained with hematoxilin end eosin (HE) to evaluate
histopathological changes. Note the marked infiltration of inflammatory
cells in the lungs of infected WT mice, which was largely absent in the
lungs of PLG-KO mice. The results shown are representative for two-
three mice for both groups. Immunohistochemistry (IHC) using a
monoclonal antibody for the influenza A virus nucleoprotein was used
to detect virus-infected cells. Cells positive for the presence of viral
antigen stained red. (B) Cytokine levels in BAL were assessed by ELISA
on the indicated days post inoculation of WT (black bars) and PLG-KO
mice (white bars) with IAV A/PR/8/34 or A/Netherlands/602/09. Data
represent mean 6 s.e.m. of 3–6 mice per group.
doi:10.1371/journal.ppat.1003229.g003
Plasminogen and Influenza A Virus Infections
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Figure 4. Plasminogen-deficiency prevents severe inflammation and virus dissemination. (A) Cytokine levels in BAL were assessed by 23-
multiplex Luminex kit (uninfected, white bars; infected, black bars) on the indicated days post inoculation of WT (top panel) and PLG-KO mice
(bottom panel) with IAV A/PR/8/34. The levels of IL-2, IL-3, IL-4, IL-5, IL-9, IL-12(p70), IL-13, IL-17 and eotaxin were below the detection limit (not
shown). Data represent mean 6 s.e.m. of 2 individual mice per group from one experiment and is representative of 2 individual experiments (total
n = 3–6 mice per group). (B) A/PR/8/34 virus titers in the indicated organs of WT (closed symbols) and PLG-KO mice (open symbols) was assessed 2
and 5 days post-inoculation.
doi:10.1371/journal.ppat.1003229.g004
Plasminogen and Influenza A Virus Infections
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Figure 5. Fibrinolysis is induced following severe influenza infections. (A) Levels of Plasminogen, Active Plasmin, FDP, D-dimer and
Fibrinogen, were determined by ELISA in the BAL of A/PR/8/34 infected or uninfected (2) C57BL/6 mice after the indicated days post-inoculation.
Markers were also evaluated in the BAL of WT or PLG-KO mice infected with A/Netherlands/602/09 virus. Data represent mean 6 s.e.m of n = 3–6
mice per group. (B) Western blot analysis for the detection of fibrinogen and FDP in the lungs of IAV-infected mice on the indicated days post
inoculation (representative of n = 3). kDa: apparent molecular weight. n =mice per group. (C) Presence of fibrinogen was assessed in the blood of
mice treated or not with Ancrod by ELISA (left panel) or Western blot analysis (right panel). The results represent the mean values 6 s.e.m from 3
individual animals per group for the ELISA. The western blot analysis is representative for results of 3 mice per group.
doi:10.1371/journal.ppat.1003229.g005
Plasminogen and Influenza A Virus Infections
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Figure 6. Effect of Ancrod treatment on inflammation and IAV pathogenesis. (A) Survival and weight loss of mice treated with Ancrod
(open symbols, n = 11) or not (closed symbols, n = 11) after infection with IAV A/PR/8/34 (squares) or uninfected mice (diamonds, n = 5). Weight loss
data represent weight average 6 s.e.m of the above indicated number of mice. (B) Cytokines levels in the BAL were measured by ELISA after A/PR/8/
34 infection of WT and PLG-KO (KO) mice treated with Ancrod (white bars) or not (black bars). Data represent mean 6 s.e.m. of n = 4 mice per group.
(C) Survival rate (left panels) and weight loss (right panels) of WT (squares) and PLG-KO (triangles) mice treated with Ancrod (open symbols) or not
(closed symbols) after intranasal inoculation with IAV A/PR/8/34 (n = 8–10 mice per group). Weight loss data represent weight average 6 s.e.m of the
above indicated number of mice.
doi:10.1371/journal.ppat.1003229.g006
Plasminogen and Influenza A Virus Infections
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of IAV infections. Consistently, evidence is accumulating that the
fibrinolytic molecule plasminogen and plasmin are critical host
factors for immune cell infiltration and cytokine production upon
injury [18–20]. The absence of plasminogen blunts inflammation
in response to several inflammatory stimuli and suppresses
development of lesions [21–23]. In our study, absence of
plasminogen also considerably reduced the extent of lung
inflammation upon IAV infection. Since severe inflammation
contributes to the pathogenicity of IAV infections of humans [2,4],
most likely the proinflammatory properties of plasminogen play a
role in the pathogenesis of these infections. IAV have the capacity
to bind plasminogen and convert it into its active form plasmin
through viral or cellular proteins like annexin-2 [11,12]. However,
the extent of plasminogen activation is strain-dependent [11],
which may explain differences in pathogenicity of IAV strains.
Mechanistically, the mode of action of plasminogen-driven lung
inflammation was through fibrinolysis. Indeed, degradation of
fibrinogen by Ancrod treatment increased pathogenicity of IAV
infection and compensated the protective effect in PLG-KO mice
or in mice in which plasminogen fibrinolytic activity was blocked
by 6-AHA treatment. Consistently, Keller et al showed an
activation of the fibrinolytic system during non-pathogenic IAV
infection in mice [15]. Remarkably, in humans increased
production of D-dimer, a marker of fibrinolysis was found to be
a risk factor for fatal outcome of H5N1 and pandemic H1N1 virus
infections [24,25]. Furthermore, IAV infections have been
associated with bleeding medical disorders [26,27]. Thus, as for
bacteria [28], the dysregulation of hemostasis by virus infections
may cause serious complications. Consistent with our results, it
was recently demonstrated that endothelial cells are central
orchestrators of cytokine amplification during IAV infections
[29]. Interestingly, plasminogen-dependent inflammation appears
early after infection with influenza virus A/PR/8/34, of which
virus replication is promoted by plasminogen. In contrast,
Figure 7. Effect of 6-aminohexanoic acid and/or Ancrod treatment on the course of IAV infection. Survival and weight loss of IAV
inoculated C57BL/6 mice treated with 6-AHA (circle) or not (squares). (A) Mice were inoculated with IAV A/PR8/34 (5,000 PFU, n = 28 or 500 PFU;
n = 11) in presence (open symbols) or absence (closed symbols) of Ancrod. 6-AHA treatment was initiated on the day of inoculation. (B) Infectious A/
PR/8/34 lung virus titers in 6-AHA treated or untreated mice. Data represent mean 6 s.e.m of 3 individual mice per group. (C) Mice were inoculated
with IAV A/PR/8/34 (n = 10), A/Netherlands/602/09 (n = 16) or A/chicken/Ivory-Coast/1787/2006 (n = 10) as indicated. 6-AHA treatment was initiated
two days post-inoculation. n = per group. Weight loss data represent weight average 6 s.e.m of the above indicated number of mice.
doi:10.1371/journal.ppat.1003229.g007
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replication of influenza virus A/Netherlands/602/09 is indepen-
dent of plasminogen and control of plasminogen activity has a
delayed impact on inflammation and disease. Thus, the capability
of plasminogen to cleave HA and promote virus replication may
also contribute to lung inflammation for some IAV strains.
Possibly, a sustained high degree of inflammation is deleterious for
the host.
Collectively, we propose a model (Figure 8) in which
plasminogen-mediated fibrinolysis increases FDP production and
vascular permeability allowing increase recruitment of inflamma-
tory cells at the site of infection. As a positive feedback loop,
plasminogen mediated virus replication may also further contrib-
ute to lung inflammation. Fibrinolysis may also allow systemic
haematogenous spread of virus. Consistently, we and others
detected IAV replication in extrapulmonary organs in plasmino-
gen-competent mice [30]. Since plasminogen is omnipresent in the
blood, it may provide certain IAV an alternative mechanism of
HA cleavage in extra-pulmonary organs [10,11]. For example, the
plasminogen-binding property of the neuraminidase of A/WSN/
33 strain is a determinant of its neurotropism and pathogenicity in
mice [12,13]. Interestingly, particular high virus titers were found
in the liver, which is the primary source of plasminogen. This may
explain why IAV can replicate in hepatocarcinoma liver HEPG-2
cells in the absence of exogenous proteases (Figure S4). Whether
plasminogen-dependent IAV replication contributes to damage of
the liver or other extra-pulmonary organs, as observed in Reye’s
syndrome or other postinfluenza complications [31] requires
further investigation. Interestingly, differences in virus replication
were not at the basis of plasminogen-dependent differences in
pathogenesis of IAV infection although it also can contribute to
exacerbation of inflammation. Indeed, A/Netherland/602/09
virus replication in the lungs was not affected by plasminogen
deficiency, while infected PLG-KO mice were protected from
infection. This is consistent with a recent report showing that
presence of critical residues in HA, necessary for cleavage by
plasmin is strain-dependent [32]. In addition, the HA of A/
chicken/Ivory-Coast/1787/2006 contains a polybasic site, which
is cleaved by furin-type proteases. This suggests that plasminogen
plays a minor role in replication of this virus, while plasminogen
deficiency still protected from infection with this virus. Alternative
proteases may thus play a more dominant role in HA cleavage and
virus replication in vivo than plasminogen [33–36].
For the clinical management of influenza patients, a limited
number of antiviral drugs are available. The use of these currently
available drugs is compromised by the emergence of virus strains
that developed resistance to these drugs. Therefore, intervention
strategies that aim at preventing deleterious inflammatory
responses after IAV infection are of interest and do not suffer
from resistance to antiviral drugs. Specifically, blocking protease
activity may be an efficient way to achieve this, as previously
suggested [37–39]. Our results are consistent with these studies but
differ in term of mechanism of action. Indeed, our results suggest a
more predominant role for proteases in lung hemostasis compared
to virus replication and HA cleavage.
In summary, our findings reveal a previously unrecognized role
for fibrinolysis and plasminogen in the pathogenesis of IAV
infections. Thus, targeting plasminogen, its conversion into
plasmin or regulating fibrinolysis may be a venue for the
development of novel intervention strategies for the treatment of
severe IAV infections.
Figure 8. Schematic overview of the proposed model for Plasminogen-mediated influenza virus pathogenesis. During IAV infection,
plasminogen is converted into plasmin. On the one hand, plasmin cleaves and activates the viral hemagglutinin, promoting IAV replication for some
influenza strains. On the other hand, plasmin promotes inflammation via fibrinolysis and increases permeability.
doi:10.1371/journal.ppat.1003229.g008
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Materials and Methods
Ethics statement
Experiments were performed according to recommendations of
the ‘‘National Commission of Animal Experiment (CNEA)’’ and
the ‘‘National Committee on the Ethic Reflexion of Animal
Experiments (CNREEA)’’. The protocol was approved by the
committee of animal experiments of the University Claude
Bernard Lyon I (Permit number: BH2008-13). All animal
experiments were also carried out under the authority of license
issued by ‘‘la direction des services Ve´te´rinaires’’ (accreditation
number 78–114). All efforts were made to minimize suffering.
Reagent
Viruses, cells, and reagents used, were: IAV A/Netherlands/
602/09 [40], A/chicken/Ivory-Coast/1787/2006 [41], A/PR/8/
34 (American Type Culture Collection, ATCC), A549 cells
(ATCC), Madin-Darby Canine Kidney cells (MDCK, ATCC),
trypsin (Becton Dickinson), plasminogen and 6-AHA (Sigma),
Ancrod (NIBSC), 23-Plex Mouse Cytokine Assay (Bio-Rad),
ELISA kits for mouse -IL-6, -KC, -–RANTES, -IFN-a -IFN-
c(R&D Systems), -plasminogen (Mybiosource), -active plasmin
(Kordia), -D-dimer, -fibrinogen and -FDP (Genway), antibodies
anti-HA (Santa Cruz), anti-tubulin (Sigma), anti-NP (ATCC), anti-
fibrinogen (Genway).
In vitro experiments and proteins detection
Blood fibrinogen and lung proteins were extracted as described
[42,43] and proteins were analyzed by western blot [44]. A549
experiments were performed as described previously [11].
Mice
Mice with a disrupted PLG gene (PLG-KO) and their WT
littermates were bred as described previously [45]. Briefly, PLG
heterozygous mice (C57BL/6 and 25% 129Sv) were crossed and
WT and PLG-KO mice offspring were genotyped by polymerase
chain reaction, which was performed, as previously described [46]
using primers amplifying the WT PLG gene (59ACTGCTGCC-
CACTGTTTGGAG 39 and 59 GATAACCTTGTAGAATT-
CAGGTC39) or the inactivated PLG gene (59ATGAACTGCAG-
GACGAGGCAG39 and 59 GCGAACAGTTCGGCTGGCGC
39). Most of the experiments were performed using 5–6 weeks old
mice. Also, males and females were used in the experiments.
Groups between WT and PLG KO mice were homogenized for
these different parameters. Except when PLG-WT and PLG-KO
mice were used, experiments were performed with six-week-old
C57BL/6 female mice (Charles River Laboratories).
Mice infection and treatment
Mice were anesthetized with ketamine (42,5 mg/kg) and inocu-
lated by the intranasal route with the indicated IAV in a volume of
25 ml. Upon inoculation, survival rates and loss of body weight was
scored daily, as previously described [47]. For weight loss curves, the
last measured value was carried forward until the end of the
observation period. Alternatively, mice were sacrificed at various pre-
fixed time points post-inoculation to perform bronchoalveolar lavages
(BAL) or to sample organs. Virus titers in organs were determined by
classical plaque assay using MDCK cells [47]. ELISA and luminex
assays were performed according to the instructions of the
manufacturer and virus titers were assessed as described [48]. Lungs
histology and immunohistochemistry were performed as described
[49]. Treatment with 6-AHA was injected intraperitoneally (30 mg
per mouse in 200 ml of physiological serum) every 6 hours for 4 days.
Ancrod was injected (1.75 unit per mouse) intraperitoneally two days
before infection for 7 days at 10 hours intervals.
Statistical analysis
Kaplan-Meier test was used for statistical analysis of survival
rates and Mann–Whitney’s test was used for lung virus titers and
ELISA results, p values,0.05, were considered statistically
significant. Two-tails analysis was performed. The number (n) of
animals per experimental group is mentioned in the figure legends.
Experiments were stratified in terms of weight, gender and age of
the mice.
Supporting Information
Figure S1 Effect of Ancrod treatment on uninfected
mice. Survival and weight loss of uninfected PLG-KO mice
treated with Ancrod (open triangle, n = 3).
(TIF)
Figure S2 Effect of 6-AHA on cytokine levels in the BAL.
Cytokine levels in the BAL of IAV-infected C57BL/6 mice,
treated or not (upper panel) with 6-AHA (lower panel) was
evaluated by multiplex assay four days post-inoculation. Only
detectable levels are shown. n = 3 mice per group. Please note the
difference in scale of y-axis between treated and untreated
animals.
(TIF)
Figure S3 Effect of Ancrod treatment and/or 6-AHA
treatment on uninfected mice. Survival and weight loss of
uninfected C57BL/6 mice treated with Ancrod and 6-AHA (open
circles, n = 5) or 6-AHA only (closed circles, n = 5).
(TIF)
Figure S4 IAV replication kinetics in HEPG-2 cells.
Replication kinetics of IAV A/PR/8/34 and A/Udorn/72 in
absence of proteases was assessed after inoculating HEPG-2 cells
at a MOI of 0.001.
(TIF)
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